Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles
NCT ID: NCT02677259
Last Updated: 2016-02-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE2
Total Enrollment
506 participants
Study Classification
INTERVENTIONAL
Study Start Date
2016-05-31
Study Completion Date
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Optimizing in vitro fertilization (IVF) success is more important than ever, in light of new public funding of IVF in Ontario, Canada. In patients undergoing IVF using gonadotropin-releasing hormone (GnRH) analogues, the luteal phase appears to be compromised, which may be a result of controlled-ovarian hyperstimulation, significant fluctuations in hormone levels, the impact of the oocyte retrieval process, or direct compromise of the corpus luteum. Progesterone support is definitely necessary during the luteal phase to facilitate implantation but whether estrogen supplementation is also needed remains unclear. The present study aims to determine whether estradiol support during the luteal phase improves clinical pregnancy rate in patients undergoing IVF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Luteal Phase Progesterone in IUI and Gonadotropin Cycles
NCT01941875
Infertility
COMPLETED
PHASE3
Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS
NCT02827656
Infertility
UNKNOWN
NA
Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle
NCT01367912
Infertility
COMPLETED
NA
Luteal Phase Support With Estradiol In Poor Responders Undergoing In Vitro Fertilization
NCT03788681
ICSI
UNKNOWN
PHASE3
Luteal Supplementation With Rec-LH After GnRH-agonist Triggering in In Vitro (IVF)
NCT00954811
Pregnancy
Pregnancy Loss
UNKNOWN
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
It is well established that the luteal phase is compromised in IVF cycles using GnRH analogues. Use of GnRH agonists or antagonists results in decreased production of estrogen and progesterone, a decrease in luteal phase length, and impaired endogenous gonadotropin secretion caused by persistent pituitary suppression. While the benefits of progesterone support during the luteal phase of an IVF cycle are well established, the role of estrogen support during the luteal phase is less clear.
The corpus luteum produces both progesterone and estradiol in support of the endometrium for implantation. Estrogen produced during the luteal phase modulates the concentration of progesterone receptors within the secretory endometrium in an effort to maintain sufficient receptor concentrations for progesterone stimulation. Stewart et al. highlighted the importance of luteal phase serum estradiol concentration after observing a significant difference in midluteal serum estradiol concentration between conception and non-conception cycles. This observation appears to hold true in patients undergoing IVF as well. Shahara et al. demonstrated that, not only the absolute estradiol level, but also the magnitude of estradiol decline (as measured by the ratio of peak estradiol at the time of hCG administration to midluteal estradiol) was predictive of IVF success. These studies support the idea that luteal phase estradiol supplementation may be important to implantation and IVF success.
Studies investigating the effect of luteal phase estradiol supplementation have produced conflicting results. In a small randomized, controlled trial (RCT) by Farhi et al., IVF patients receiving both oral estradiol and vaginal progesterone luteal phase support achieved higher clinical pregnancy and implantation rates than patients received vaginal progesterone alone. Lukaszuk et al. confirmed these findings and found that the most significant benefit occurred at the highest dose of estradiol administered (6mg). Elgindy et al. observed a correlation between mid-luteal serum estradiol concentration and clinical pregnancy rates in patients receiving 6mg of oral estradiol15. Similar benefits of luteal phase estradiol support have been demonstrated in both vaginal and transdermal formulations.
Conversely, multiple older studies have failed to demonstrate a benefit of luteal phase estradiol support in IVF cycles. Lin et al., in a RCT of 402 patients undergoing IVF, found no benefit of luteal phase oral estradiol. This finding was supported by studies investigating both vaginal and transdermal formulations of luteal phase estradiol support. A recent meta-analysis also did not demonstrate a statistically significant benefit of luteal phase estradiol administration to IVF outcomes, though the common odds ratio was 1.18 (95% CI: 0.98, 1.41) with a p value of 0.07. Significant heterogeneity was observed between the included studies and the authors admit that more large-scale RCTs are needed to appropriately address this question.
Since these trials were done, there has been a major shift away from long GnRH agonist stimulation to short protocol GnRH antagonist use. All but three of the studies of luteal phase estradiol support have focused on IVF cycles using the old GnRH agonist protocols given the frequency of their application. The few studies using GnRH antagonist protocols have not shown a benefit of luteal phase estradiol support but these studies have been small in scale (total n=426) or failed to report on important outcomes such as clinical pregnancy rate. Both GnRH agonists and antagonists suppress pituitary gonadotropin production and lead to a luteal phase deficiency. GnRH antagonists appear to promote premature luteolysis causing a reduction in luteal phase length and ultimately decreased pregnancy rates. Given the frequency with which these protocols are now used in IVF, a large-scale study is greatly needed to address the role of estradiol luteal phase supplementation.
It is well established that the luteal phase in IVF cycles using GnRH analogues is compromised and some form of luteal phase support is required. Compelling evidence exists to support the use of luteal phase progesterone but the role of estradiol remains controversial. Most of the existing studies are small in size and lack sufficient power. Few studies exist to determine the role of estrogen supplementation in GnRH antagonist IVF cycles. This well-powered RCT will address this important clinical question.
Methods:
Design: This is a single center RCT, conducted at ONE Fertility Burlington.
Inclusion criteria: Indications for IVF/ICSI include male factor, diminished ovarian reserve, tubal factor, ovulatory dysfunction and unexplained infertility. Female age will be 42 years or less.
IVF protocol: A short, GnRH antagonist protocol will be used for all patients. Starting on cycle day 3, ovarian stimulation will be performed using a combination of recombinant follicle-stimulating hormone (FSH) (Puregon, Ferring, or; Gonal-F, EMD Serono), medications mimicking luteinizing hormone (LH) activity, i.e recombinant human choriogonadotropin (hCG, Ferring) and/or medications containing both FSH and LH (Menopur, Ferring). Medications will be dosed according to the patient's diagnosis and ovarian reserve measurements. Follicular development will be monitored with serial transvaginal ultrasounds, and serum estradiol, progesterone and LH concentrations. A GnRH antagonist (Orgalutran, EMD Serono) will be commenced for pituitary suppression between cycle day 6 to 9. Oocyte retrieval will be performed 36 hours after administration of choriogonadotropin alpha (Ovidrel, EMD Serono), or a GnRH agonist (Decapeptyl, Ferring), to complete oocyte maturation once a sufficient cohort of mature follicles has been identified. A maximum of 2 embryos will be transferred on either day 3 or day 5 following oocyte retrieval. Serum beta hCG measurement will be performed 17 days after oocyte retrieval and, if positive, clinical pregnancy will be confirmed every 2 weeks commencing at 6 weeks gestation until 12 weeks gestation.
Recruitment and Randomization: Recruitment will occur and informed consent will be obtained at the time of treatment consent. Participants will be randomized at the time of recruitment by way of numbered, sealed envelopes to receive either 17-beta estradiol 3 mg PO/PV BID plus micronized progesterone 200 mg PV TID (treatment group) or micronized progesterone alone (control group) for luteal support commencing the day after oocyte retrieval. 17-beta estradiol will be continued until the time of pregnancy testing and, if β-hCG is positive, until 6 weeks gestation (4 weeks total). Progesterone will be continued until the time of pregnancy testing and, if β-hCG is positive, until 10 weeks gestation (8 weeks total). There will be no blinding to group allocation and no placebo. Subjects will be assigned a unique subject number prior to data analysis in order to avoid the use of any identifying information. Data will be collected using a standardized patient data form in a secure computerized database.
Outcomes: The primary outcome is clinical pregnancy, defined as the presence of fetal heart activity on ultrasound at or beyond 6 weeks gestation. Secondary outcomes include ongoing pregnancy rate (number of clinical pregnancies on ultrasound continuing beyond 12 weeks gestation/number of clinical pregnancies), implantation rate (number of clinical pregnancies/number of embryos transferred), luteal phase serum estradiol and progesterone concentration (performed at oocyte retrieval, 10 days after retrieval, and at the time of serum pregnancy testing, i.e. 17 days after retrieval), miscarriage rate (number of pregnancy losses before 20 weeks/number of clinical pregnancies) and ectopic pregnancy rate (number of ectopic pregnancies on ultrasound/number of clinical pregnancies).
Data Analysis: Descriptive analyses will be performed using SPSS software (IBM Corp., Version 22). Associations between categorical variables will be analyzed using a combination of Chi-square and Fisher's Exact tests. Associations between continuous variables will be analyzed using a combination of independent sample t-tests and logistic regression.
Sample Size Calculation: Based on a sample size calculation with assumptions of ß = 80%, α = 0.05 and an effect size of 25% in clinical pregnancy rate, a total of 506 subjects (253 per arm) will need to be recruited. This is feasible within this center over a two-year period or less, based on the current number of stimulated cycles per year of 360 and a high rate of compliance and patient interest in the study.
It is well established that the luteal phase is compromised in IVF cycles using GnRH analogues. Use of GnRH agonists or antagonists results in decreased production of estrogen and progesterone, a decrease in luteal phase length, and impaired endogenous gonadotropin secretion caused by persistent pituitary suppression. While the benefits of progesterone support during the luteal phase of an IVF cycle are well established, the role of estrogen support during the luteal phase is less clear.
The corpus luteum produces both progesterone and estradiol in support of the endometrium for implantation. Estrogen produced during the luteal phase modulates the concentration of progesterone receptors within the secretory endometrium in an effort to maintain sufficient receptor concentrations for progesterone stimulation. Stewart et al. highlighted the importance of luteal phase serum estradiol concentration after observing a significant difference in midluteal serum estradiol concentration between conception and non-conception cycles. This observation appears to hold true in patients undergoing IVF as well. Shahara et al. demonstrated that, not only the absolute estradiol level, but also the magnitude of estradiol decline (as measured by the ratio of peak estradiol at the time of hCG administration to midluteal estradiol) was predictive of IVF success. These studies support the idea that luteal phase estradiol supplementation may be important to implantation and IVF success.
Studies investigating the effect of luteal phase estradiol supplementation have produced conflicting results. In a small randomized, controlled trial (RCT) by Farhi et al., IVF patients receiving both oral estradiol and vaginal progesterone luteal phase support achieved higher clinical pregnancy and implantation rates than patients received vaginal progesterone alone. Lukaszuk et al. confirmed these findings and found that the most significant benefit occurred at the highest dose of estradiol administered (6mg). Elgindy et al. observed a correlation between mid-luteal serum estradiol concentration and clinical pregnancy rates in patients receiving 6mg of oral estradiol15. Similar benefits of luteal phase estradiol support have been demonstrated in both vaginal and transdermal formulations.
Conversely, multiple older studies have failed to demonstrate a benefit of luteal phase estradiol support in IVF cycles. Lin et al., in a RCT of 402 patients undergoing IVF, found no benefit of luteal phase oral estradiol. This finding was supported by studies investigating both vaginal and transdermal formulations of luteal phase estradiol support. A recent meta-analysis also did not demonstrate a statistically significant benefit of luteal phase estradiol administration to IVF outcomes, though the common odds ratio was 1.18 (95% CI: 0.98, 1.41) with a p value of 0.07. Significant heterogeneity was observed between the included studies and the authors admit that more large-scale RCTs are needed to appropriately address this question.
Since these trials were done, there has been a major shift away from long GnRH agonist stimulation to short protocol GnRH antagonist use. All but three of the studies of luteal phase estradiol support have focused on IVF cycles using the old GnRH agonist protocols given the frequency of their application. The few studies using GnRH antagonist protocols have not shown a benefit of luteal phase estradiol support but these studies have been small in scale (total n=426) or failed to report on important outcomes such as clinical pregnancy rate. Both GnRH agonists and antagonists suppress pituitary gonadotropin production and lead to a luteal phase deficiency. GnRH antagonists appear to promote premature luteolysis causing a reduction in luteal phase length and ultimately decreased pregnancy rates. Given the frequency with which these protocols are now used in IVF, a large-scale study is greatly needed to address the role of estradiol luteal phase supplementation.
It is well established that the luteal phase in IVF cycles using GnRH analogues is compromised and some form of luteal phase support is required. Compelling evidence exists to support the use of luteal phase progesterone but the role of estradiol remains controversial. Most of the existing studies are small in size and lack sufficient power. Few studies exist to determine the role of estrogen supplementation in GnRH antagonist IVF cycles. This well-powered RCT will address this important clinical question.
Methods:
Design: This is a single center RCT, conducted at ONE Fertility Burlington.
Inclusion criteria: Indications for IVF/ICSI include male factor, diminished ovarian reserve, tubal factor, ovulatory dysfunction and unexplained infertility. Female age will be 42 years or less.
IVF protocol: A short, GnRH antagonist protocol will be used for all patients. Starting on cycle day 3, ovarian stimulation will be performed using a combination of recombinant follicle-stimulating hormone (FSH) (Puregon, Ferring, or; Gonal-F, EMD Serono), medications mimicking luteinizing hormone (LH) activity, i.e recombinant human choriogonadotropin (hCG, Ferring) and/or medications containing both FSH and LH (Menopur, Ferring). Medications will be dosed according to the patient's diagnosis and ovarian reserve measurements. Follicular development will be monitored with serial transvaginal ultrasounds, and serum estradiol, progesterone and LH concentrations. A GnRH antagonist (Orgalutran, EMD Serono) will be commenced for pituitary suppression between cycle day 6 to 9. Oocyte retrieval will be performed 36 hours after administration of choriogonadotropin alpha (Ovidrel, EMD Serono), or a GnRH agonist (Decapeptyl, Ferring), to complete oocyte maturation once a sufficient cohort of mature follicles has been identified. A maximum of 2 embryos will be transferred on either day 3 or day 5 following oocyte retrieval. Serum beta hCG measurement will be performed 17 days after oocyte retrieval and, if positive, clinical pregnancy will be confirmed every 2 weeks commencing at 6 weeks gestation until 12 weeks gestation.
Recruitment and Randomization: Recruitment will occur and informed consent will be obtained at the time of treatment consent. Participants will be randomized at the time of recruitment by way of numbered, sealed envelopes to receive either 17-beta estradiol 3 mg PO/PV BID plus micronized progesterone 200 mg PV TID (treatment group) or micronized progesterone alone (control group) for luteal support commencing the day after oocyte retrieval. 17-beta estradiol will be continued until the time of pregnancy testing and, if β-hCG is positive, until 6 weeks gestation (4 weeks total). Progesterone will be continued until the time of pregnancy testing and, if β-hCG is positive, until 10 weeks gestation (8 weeks total). There will be no blinding to group allocation and no placebo. Subjects will be assigned a unique subject number prior to data analysis in order to avoid the use of any identifying information. Data will be collected using a standardized patient data form in a secure computerized database.
Outcomes: The primary outcome is clinical pregnancy, defined as the presence of fetal heart activity on ultrasound at or beyond 6 weeks gestation. Secondary outcomes include ongoing pregnancy rate (number of clinical pregnancies on ultrasound continuing beyond 12 weeks gestation/number of clinical pregnancies), implantation rate (number of clinical pregnancies/number of embryos transferred), luteal phase serum estradiol and progesterone concentration (performed at oocyte retrieval, 10 days after retrieval, and at the time of serum pregnancy testing, i.e. 17 days after retrieval), miscarriage rate (number of pregnancy losses before 20 weeks/number of clinical pregnancies) and ectopic pregnancy rate (number of ectopic pregnancies on ultrasound/number of clinical pregnancies).
Data Analysis: Descriptive analyses will be performed using SPSS software (IBM Corp., Version 22). Associations between categorical variables will be analyzed using a combination of Chi-square and Fisher's Exact tests. Associations between continuous variables will be analyzed using a combination of independent sample t-tests and logistic regression.
Sample Size Calculation: Based on a sample size calculation with assumptions of ß = 80%, α = 0.05 and an effect size of 25% in clinical pregnancy rate, a total of 506 subjects (253 per arm) will need to be recruited. This is feasible within this center over a two-year period or less, based on the current number of stimulated cycles per year of 360 and a high rate of compliance and patient interest in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
IVF
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Estradiol + Standard Luteal Phase Support
1. 17-beta estradiol 3 mg PO/PV BID from day of oocyte retrieval until 6 weeks gestation
2. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
Group Type
EXPERIMENTAL
17-beta estradiol
Intervention Type
DRUG
Micronized progesterone
Intervention Type
DRUG
Standard Luteal Phase Support
1\. Micronized progesterone 200 mg PV TID from day of oocyte retrieval until 10 weeks gestation
Group Type
ACTIVE_COMPARATOR
Micronized progesterone
Intervention Type
DRUG
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
17-beta estradiol
Intervention Type
DRUG
Micronized progesterone
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Estrace
Endometrin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indications for IVF/ICSI include male factor, diminished ovarian reserve, tubal factor, ovulatory dysfunction and unexplained infertility.
Exclusion Criteria
* none
Minimum Eligible Age
18 Years
Maximum Eligible Age
42 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
One Fertility
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Evan Taerk
Dr. Evan Taerk
Responsibility Role
PRINCIPAL_INVESTIGATOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the luteal phase of in vitro fertilization cycles: a meta-analysis. Fertil Steril. 2010 Feb;93(2):428-36. doi: 10.1016/j.fertnstert.2009.02.033. Epub 2009 Apr 1.
Reference Type
BACKGROUND
Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, Van Waesberghe L, Wisanto A, Van Steirteghem AC. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988 Jul;3(5):585-90. doi: 10.1093/oxfordjournals.humrep.a136750.
Reference Type
BACKGROUND
Smith EM, Anthony FW, Gadd SC, Masson GM. Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. BMJ. 1989 Jun 3;298(6686):1483-6. doi: 10.1136/bmj.298.6686.1483.
Reference Type
BACKGROUND
Belaisch-Allart J, De Mouzon J, Lapousterle C, Mayer M. The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Hum Reprod. 1990 Feb;5(2):163-6. doi: 10.1093/oxfordjournals.humrep.a137062.
Reference Type
BACKGROUND
van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015 Jul 7;2015(7):CD009154. doi: 10.1002/14651858.CD009154.pub3.
Reference Type
BACKGROUND
Fritz MA, Westfahl PK, Graham RL. The effect of luteal phase estrogen antagonism on endometrial development and luteal function in women. J Clin Endocrinol Metab. 1987 Nov;65(5):1006-13. doi: 10.1210/jcem-65-5-1006.
Reference Type
BACKGROUND
Goldstein D, Zuckerman H, Harpaz S, Barkai J, Geva A, Gordon S, Shalev E, Schwartz M. Correlation between estradiol and progesterone in cycles with luteal phase deficiency. Fertil Steril. 1982 Mar;37(3):348-54.
Reference Type
BACKGROUND
Ganesh A, Goswami S, Chattopadhyay R, Chakraborty C, Chaudhury K, Chakravarty BN. Luteal phase estradiol level: a potential predictive marker for successful pregnancy in in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2009 Apr;91(4):1018-22. doi: 10.1016/j.fertnstert.2008.01.074. Epub 2008 Mar 21.
Reference Type
BACKGROUND
Hutchinson-Williams KA, Lunenfeld B, Diamond MP, Lavy G, Boyers SP, DeCherney AH. Human chorionic gonadotropin, estradiol, and progesterone profiles in conception and nonconception cycles in an in vitro fertilization program. Fertil Steril. 1989 Sep;52(3):441-5. doi: 10.1016/s0015-0282(16)60915-9.
Reference Type
BACKGROUND
Emperaire JC, Ruffie A, Audebert AJ, Verdaguer S. Early prognosis for IVF pregnancies through plasma oestrogens. Lancet. 1984 Nov 17;2(8412):1151. doi: 10.1016/s0140-6736(84)91577-0. No abstract available.
Reference Type
BACKGROUND
Sharara FI, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum Reprod. 1999 Nov;14(11):2777-82. doi: 10.1093/humrep/14.11.2777.
Reference Type
BACKGROUND
Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2000 Apr;73(4):761-6. doi: 10.1016/s0015-0282(99)00632-9.
Reference Type
BACKGROUND
Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2005 May;83(5):1372-6. doi: 10.1016/j.fertnstert.2004.11.055.
Reference Type
BACKGROUND
Var T, Tonguc EA, Doganay M, Gulerman C, Gungor T, Mollamahmutoglu L. A comparison of the effects of three different luteal phase support protocols on in vitro fertilization outcomes: a randomized clinical trial. Fertil Steril. 2011 Mar 1;95(3):985-9. doi: 10.1016/j.fertnstert.2010.06.057. Epub 2010 Aug 2.
Reference Type
BACKGROUND
Elgindy EA, El-Haieg DO, Mostafa MI, Shafiek M. Does luteal estradiol supplementation have a role in long agonist cycles? Fertil Steril. 2010 May 1;93(7):2182-8. doi: 10.1016/j.fertnstert.2009.01.066. Epub 2009 Feb 24.
Reference Type
BACKGROUND
Gorkemli H, Ak D, Akyurek C, Aktan M, Duman S. Comparison of pregnancy outcomes of progesterone or progesterone + estradiol for luteal phase support in ICSI-ET cycles. Gynecol Obstet Invest. 2004;58(3):140-4. doi: 10.1159/000079115. Epub 2004 Jun 15.
Reference Type
BACKGROUND
Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril. 2008 Mar;89(3):554-61. doi: 10.1016/j.fertnstert.2007.04.006. Epub 2007 Aug 2.
Reference Type
BACKGROUND
Ceyhan ST, Basaran M, Kemal Duru N, Yilmaz A, Goktolga U, Baser I. Use of luteal estrogen supplementation in normal responder patients treated with fixed multidose GnRH antagonist: a prospective randomized controlled study. Fertil Steril. 2008 Jun;89(6):1827-30. doi: 10.1016/j.fertnstert.2007.08.029. Epub 2007 Dec 11.
Reference Type
BACKGROUND
Huang N, Situ B, Chen X, Liu J, Yan P, Kang X, Kong S, Huang M. Meta-analysis of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2015 Feb;103(2):367-73.e5. doi: 10.1016/j.fertnstert.2014.10.029. Epub 2014 Dec 6.
Reference Type
BACKGROUND
Fatemi HM, Kolibianakis EM, Camus M, Tournaye H, Donoso P, Papanikolaou E, Devroey P. Addition of estradiol to progesterone for luteal supplementation in patients stimulated with GnRH antagonist/rFSH for IVF: a randomized controlled trial. Hum Reprod. 2006 Oct;21(10):2628-32. doi: 10.1093/humrep/del117. Epub 2006 Jul 20.
Reference Type
BACKGROUND
Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab. 2003 Sep;88(9):4186-92. doi: 10.1210/jc.2002-021953.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0564
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI
NCT03677336
COMPLETED
PHASE4
Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT
NCT01790282
COMPLETED
NA
Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles
NCT04758871
COMPLETED
PHASE4
Efficacy and Safety of Medication Used to Stimulate Ovulation
NCT02715336
UNKNOWN
PHASE4
Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates
NCT01237535
UNKNOWN
PHASE4
Intrauterine Insemination and Luteal Fase Support
NCT01826747
COMPLETED
PHASE4
Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support
NCT05969795
RECRUITING
PHASE1
Luteal Phase Support In IVF Women Using GnRH Agonist
NCT04174378
COMPLETED
Luteal-Phase GnRH Agonist Administration in Frozen-Thawed IVF Embryo Transfer Cycles
NCT00542126
UNKNOWN
NA
Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response
NCT02798653
UNKNOWN
PHASE3
Oral Dydrogesterone vs. Vaginal Micronized Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer
NCT03832699
UNKNOWN
NA
GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles
NCT02262416
UNKNOWN
PHASE3
Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles
NCT06150703
RECRUITING
PHASE3
The Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF Treatment
NCT00490308
UNKNOWN
PHASE1
GnRH for Luteal Support in IVF/ICSI/FET Cycles
NCT02357654
RECRUITING
PHASE4
Effect of Timing Progesterone Luteal Support on Embryo Transfer
NCT03040830
COMPLETED
PHASE4
Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles
NCT03181685
TERMINATED
PHASE4
GnRH Agonist as Luteal Support in FET Cycles
NCT02620124
COMPLETED
PHASE4
Optimizing Ovulation Induction in the Poor Responder
NCT01200537
WITHDRAWN
NA
The Effects of Intrauterine Infusion of hCG at the Time of Embryo Transfer
NCT02668965
UNKNOWN
NA
GnRH Agonist for Luteal Phase Support.
NCT05484193
UNKNOWN
NA
Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone
NCT06870266
NOT_YET_RECRUITING
EARLY_PHASE1
Timing of Initiation of Luteal Phase Support in Poor Responders Undergoing IVF/ICSI
NCT03938064
UNKNOWN
PHASE4
Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support
NCT03734770
COMPLETED
NA
Luteal Support and Intrauterine Insemination (IUI) With Clomiphene Citrate
NCT01046708
COMPLETED
NA